Addition of Rosiglitazone to Glimepirid and Metformin Combination Therapy in Type 2 Diabetes

DOI Web Site PubMed 被引用文献1件 参考文献48件
  • ORBAY Ekrem
    Department of Endocrinology and Diabetes, Internal Medicine Clinic, Kartal Education and Research Hospital
  • SARGIN Mehmet
    Department of Endocrinology and Diabetes, Internal Medicine Clinic, Kartal Education and Research Hospital
  • SARGIN Haluk
    Department of Endocrinology and Diabetes, Internal Medicine Clinic, Kartal Education and Research Hospital
  • GÖZÜ Hülya
    Department of Endocrinology and Diabetes, Internal Medicine Clinic, Kartal Education and Research Hospital
  • BAYRAMIÇLI Oya Uygur
    Department of Gastroenterology, Internal Medicine Clinic, Kartal Education and Research Hospital
  • YAYLA ALl
    Department of Endocrinology and Diabetes, Internal Medicine Clinic, Kartal Education and Research Hospital

この論文をさがす

抄録

The study was planned to determine the efficacy and safety of adding rosiglitazone to a combination of glimepiride and metformin therapy with insufficiently controlled type 2 diabetes. This was an open-label study with a follow-up period of 26 weeks. Thirty patients were taking 3 mg glimepiride two times and 850 mg metformin two times per day. Patients were told to take one rosiglitazone 4 mg tablet before breakfast additionally. The primary efficacy measure was the mean change in HbA1c from baseline to the end of the study. Secondary efficacy parameters included the mean changes from baseline to the end of the study in fasting plasma glucose (FPG) and insulin levels, as well as total cholesterol, HDL-C, LDL-C, triglycerides, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. Mean HbA1c levels decreased significantly from 7.54 ± 0.9% to 6.57 ± 0.7% (p<0,001) at 26th week. FPG levels fell from 169.39 ± 37.8 mg/dl to 135.69 ± 28.0 mg/dl (p<0.001), respectively. Insulin levels decreased from 19.60 ± 9.8 U/L to 14.66 ± 11.6 U/L (p = 0,026) at 26th week. No one experienced elevations of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels greater than 2.5 times the upper limit of the reference range. This study confirms that the addition of rosiglitazone (4 mg/day) to sulphonylurea and metformin treatment for patients with type 2 diabetes improves glycemic control, is safe, and generally well tolerated.<br>

収録刊行物

  • Endocrine Journal

    Endocrine Journal 51 (6), 521-527, 2004

    一般社団法人 日本内分泌学会

被引用文献 (1)*注記

もっと見る

参考文献 (48)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ